A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years

Raymond H. Thornton, Anne Covey, Elena N. Petre, Elyn R. Riedel, Mary Maluccio, Constantinos T. Sofocleous, Lynn A. Brody, George I. Getrajdman, Michael D'Angelica, Yuman Fong, Karen T. Brown

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

BACKGROUND: The objective of this study was to compare the morbidity, mortality, and survival of patients aged <70 years and aged ≥70 years who underwent hepatic arterial embolization (HAE) for the treatment of hepatocellular carcinoma (HCC). METHODS: Between 1997 and 2007, 386 patients underwent HAE for HCC at a single center. Two hundred patients were aged <70 years (153 men; median age, 60 years), and 186 patients were aged ≥70 years (128 men; median age, 75 years). Patients underwent a total 965 embolization procedures (median, 2 procedures per patient). Patient demographics, morbidity, mortality, length of hospital stay, and survival were analyzed. Complications were categorized using Common Terminology Criteria for Adverse Events, version 3.0 guidelines. Survival was calculated by using the Kaplan-Meier method. RESULTS: There were no significant differences between younger and older groups in the incidence of infectious, hepatobiliary, renal, vascular, or miscellaneous complications (P ≥ .05); complication severity (P = .82); procedural mortality (P = .63); length of hospitalization (P = .55); intensive care unit admission (P = .64); or overall survival (P = .30). There were more cardiopulmonary complications in the older group (P = .04), but the association of age and likelihood of a cardiopulmonary complication lost significance after adjusting for the presence of more cardiovascular comorbidities in the older group (P = .08). CONCLUSIONS: Survival and mortality outcomes of HAE for the treatment of HCC were similar whether patients were aged <70 years or ≥70 years. Although patients aged ≥70 years with cardiovascular comorbidities more often had a cardiopulmonary complication, other morbidity measures, including complication severity, need for intensive care unit admission, and length of hospitalization, were similar between groups.

Original languageEnglish
Pages (from-to)5000-5006
Number of pages7
JournalCancer
Volume115
Issue number21
DOIs
StatePublished - Nov 1 2009

Fingerprint

Hepatic Artery
Hepatocellular Carcinoma
Survival
Mortality
Morbidity
Intensive Care Units
Comorbidity
Liver
Length of Stay
Hospitalization
Terminology
Blood Vessels
Demography
Guidelines
Kidney
Incidence
Therapeutics

Keywords

  • Age
  • Hepatocellular carcinoma
  • Morbidity
  • Mortality
  • Transcatheter arterial embolization

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Thornton, R. H., Covey, A., Petre, E. N., Riedel, E. R., Maluccio, M., Sofocleous, C. T., ... Brown, K. T. (2009). A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years. Cancer, 115(21), 5000-5006. https://doi.org/10.1002/cncr.24556

A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years. / Thornton, Raymond H.; Covey, Anne; Petre, Elena N.; Riedel, Elyn R.; Maluccio, Mary; Sofocleous, Constantinos T.; Brody, Lynn A.; Getrajdman, George I.; D'Angelica, Michael; Fong, Yuman; Brown, Karen T.

In: Cancer, Vol. 115, No. 21, 01.11.2009, p. 5000-5006.

Research output: Contribution to journalArticle

Thornton, RH, Covey, A, Petre, EN, Riedel, ER, Maluccio, M, Sofocleous, CT, Brody, LA, Getrajdman, GI, D'Angelica, M, Fong, Y & Brown, KT 2009, 'A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years', Cancer, vol. 115, no. 21, pp. 5000-5006. https://doi.org/10.1002/cncr.24556
Thornton, Raymond H. ; Covey, Anne ; Petre, Elena N. ; Riedel, Elyn R. ; Maluccio, Mary ; Sofocleous, Constantinos T. ; Brody, Lynn A. ; Getrajdman, George I. ; D'Angelica, Michael ; Fong, Yuman ; Brown, Karen T. / A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years. In: Cancer. 2009 ; Vol. 115, No. 21. pp. 5000-5006.
@article{811249ca5fd943d5a3cb402cff1204f4,
title = "A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years",
abstract = "BACKGROUND: The objective of this study was to compare the morbidity, mortality, and survival of patients aged <70 years and aged ≥70 years who underwent hepatic arterial embolization (HAE) for the treatment of hepatocellular carcinoma (HCC). METHODS: Between 1997 and 2007, 386 patients underwent HAE for HCC at a single center. Two hundred patients were aged <70 years (153 men; median age, 60 years), and 186 patients were aged ≥70 years (128 men; median age, 75 years). Patients underwent a total 965 embolization procedures (median, 2 procedures per patient). Patient demographics, morbidity, mortality, length of hospital stay, and survival were analyzed. Complications were categorized using Common Terminology Criteria for Adverse Events, version 3.0 guidelines. Survival was calculated by using the Kaplan-Meier method. RESULTS: There were no significant differences between younger and older groups in the incidence of infectious, hepatobiliary, renal, vascular, or miscellaneous complications (P ≥ .05); complication severity (P = .82); procedural mortality (P = .63); length of hospitalization (P = .55); intensive care unit admission (P = .64); or overall survival (P = .30). There were more cardiopulmonary complications in the older group (P = .04), but the association of age and likelihood of a cardiopulmonary complication lost significance after adjusting for the presence of more cardiovascular comorbidities in the older group (P = .08). CONCLUSIONS: Survival and mortality outcomes of HAE for the treatment of HCC were similar whether patients were aged <70 years or ≥70 years. Although patients aged ≥70 years with cardiovascular comorbidities more often had a cardiopulmonary complication, other morbidity measures, including complication severity, need for intensive care unit admission, and length of hospitalization, were similar between groups.",
keywords = "Age, Hepatocellular carcinoma, Morbidity, Mortality, Transcatheter arterial embolization",
author = "Thornton, {Raymond H.} and Anne Covey and Petre, {Elena N.} and Riedel, {Elyn R.} and Mary Maluccio and Sofocleous, {Constantinos T.} and Brody, {Lynn A.} and Getrajdman, {George I.} and Michael D'Angelica and Yuman Fong and Brown, {Karen T.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1002/cncr.24556",
language = "English",
volume = "115",
pages = "5000--5006",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "21",

}

TY - JOUR

T1 - A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years

AU - Thornton, Raymond H.

AU - Covey, Anne

AU - Petre, Elena N.

AU - Riedel, Elyn R.

AU - Maluccio, Mary

AU - Sofocleous, Constantinos T.

AU - Brody, Lynn A.

AU - Getrajdman, George I.

AU - D'Angelica, Michael

AU - Fong, Yuman

AU - Brown, Karen T.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - BACKGROUND: The objective of this study was to compare the morbidity, mortality, and survival of patients aged <70 years and aged ≥70 years who underwent hepatic arterial embolization (HAE) for the treatment of hepatocellular carcinoma (HCC). METHODS: Between 1997 and 2007, 386 patients underwent HAE for HCC at a single center. Two hundred patients were aged <70 years (153 men; median age, 60 years), and 186 patients were aged ≥70 years (128 men; median age, 75 years). Patients underwent a total 965 embolization procedures (median, 2 procedures per patient). Patient demographics, morbidity, mortality, length of hospital stay, and survival were analyzed. Complications were categorized using Common Terminology Criteria for Adverse Events, version 3.0 guidelines. Survival was calculated by using the Kaplan-Meier method. RESULTS: There were no significant differences between younger and older groups in the incidence of infectious, hepatobiliary, renal, vascular, or miscellaneous complications (P ≥ .05); complication severity (P = .82); procedural mortality (P = .63); length of hospitalization (P = .55); intensive care unit admission (P = .64); or overall survival (P = .30). There were more cardiopulmonary complications in the older group (P = .04), but the association of age and likelihood of a cardiopulmonary complication lost significance after adjusting for the presence of more cardiovascular comorbidities in the older group (P = .08). CONCLUSIONS: Survival and mortality outcomes of HAE for the treatment of HCC were similar whether patients were aged <70 years or ≥70 years. Although patients aged ≥70 years with cardiovascular comorbidities more often had a cardiopulmonary complication, other morbidity measures, including complication severity, need for intensive care unit admission, and length of hospitalization, were similar between groups.

AB - BACKGROUND: The objective of this study was to compare the morbidity, mortality, and survival of patients aged <70 years and aged ≥70 years who underwent hepatic arterial embolization (HAE) for the treatment of hepatocellular carcinoma (HCC). METHODS: Between 1997 and 2007, 386 patients underwent HAE for HCC at a single center. Two hundred patients were aged <70 years (153 men; median age, 60 years), and 186 patients were aged ≥70 years (128 men; median age, 75 years). Patients underwent a total 965 embolization procedures (median, 2 procedures per patient). Patient demographics, morbidity, mortality, length of hospital stay, and survival were analyzed. Complications were categorized using Common Terminology Criteria for Adverse Events, version 3.0 guidelines. Survival was calculated by using the Kaplan-Meier method. RESULTS: There were no significant differences between younger and older groups in the incidence of infectious, hepatobiliary, renal, vascular, or miscellaneous complications (P ≥ .05); complication severity (P = .82); procedural mortality (P = .63); length of hospitalization (P = .55); intensive care unit admission (P = .64); or overall survival (P = .30). There were more cardiopulmonary complications in the older group (P = .04), but the association of age and likelihood of a cardiopulmonary complication lost significance after adjusting for the presence of more cardiovascular comorbidities in the older group (P = .08). CONCLUSIONS: Survival and mortality outcomes of HAE for the treatment of HCC were similar whether patients were aged <70 years or ≥70 years. Although patients aged ≥70 years with cardiovascular comorbidities more often had a cardiopulmonary complication, other morbidity measures, including complication severity, need for intensive care unit admission, and length of hospitalization, were similar between groups.

KW - Age

KW - Hepatocellular carcinoma

KW - Morbidity

KW - Mortality

KW - Transcatheter arterial embolization

UR - http://www.scopus.com/inward/record.url?scp=70350519956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350519956&partnerID=8YFLogxK

U2 - 10.1002/cncr.24556

DO - 10.1002/cncr.24556

M3 - Article

VL - 115

SP - 5000

EP - 5006

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 21

ER -